X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1116) 1116
male (780) 780
female (629) 629
index medicus (629) 629
animals (592) 592
tetrahydroisoquinolines - therapeutic use (542) 542
tetrahydroisoquinolines (536) 536
middle aged (458) 458
pharmacology & pharmacy (456) 456
tetrahydroisoquinolines - pharmacology (365) 365
aged (358) 358
adult (340) 340
isoquinolines - therapeutic use (335) 335
angiotensin-converting enzyme inhibitors - therapeutic use (318) 318
rats (280) 280
oncology (259) 259
treatment outcome (247) 247
tetrahydroisoquinolines - administration & dosage (228) 228
dioxoles - therapeutic use (226) 226
quinapril (226) 226
trabectedin (201) 201
solifenacin succinate (199) 199
tetrahydroisoquinolines - adverse effects (191) 191
mice (189) 189
dose-response relationship, drug (184) 184
isoquinolines - pharmacology (184) 184
hypertension - drug therapy (181) 181
antineoplastic agents, alkylating - therapeutic use (174) 174
quinuclidines - therapeutic use (162) 162
blood pressure - drug effects (156) 156
cancer (138) 138
muscarinic antagonists - therapeutic use (137) 137
chemotherapy (135) 135
double-blind method (133) 133
urinary bladder, overactive - drug therapy (125) 125
analysis (119) 119
sarcoma - drug therapy (116) 116
tetrahydroisoquinolines - chemistry (116) 116
chemistry, medicinal (114) 114
dioxoles - administration & dosage (110) 110
dioxoles - adverse effects (109) 109
angiotensin-converting enzyme inhibitors - pharmacology (108) 108
cardiac & cardiovascular systems (106) 106
antihypertensive agents - therapeutic use (103) 103
time factors (102) 102
tetrahydroisoquinolines - pharmacokinetics (100) 100
aged, 80 and over (98) 98
in-vitro (98) 98
hypertension (97) 97
pharmacology/toxicology (94) 94
care and treatment (93) 93
rats, sprague-dawley (93) 93
medicine & public health (92) 92
et-743 (90) 90
sarcoma (90) 90
overactive bladder (89) 89
drug therapy, combination (88) 88
pharmacokinetics (87) 87
isoquinolines - adverse effects (86) 86
urology & nephrology (86) 86
ecteinascidin-743 (83) 83
antineoplastic combined chemotherapy protocols - therapeutic use (81) 81
drug therapy (80) 80
hypertension - physiopathology (80) 80
p-glycoprotein (78) 78
phase-ii (78) 78
dioxoles - pharmacology (77) 77
neurosciences (77) 77
prospective studies (76) 76
adolescent (74) 74
efficacy (73) 73
rats, wistar (73) 73
tetrahydroisoquinoline (73) 73
antineoplastic agents, alkylating - adverse effects (72) 72
cell line, tumor (72) 72
disease models, animal (72) 72
peripheral vascular disease (71) 71
young adult (71) 71
quinuclidines - adverse effects (70) 70
solifenacin (70) 70
acridines - pharmacology (69) 69
angiotensin-converting enzyme inhibitors - adverse effects (69) 69
research (68) 68
biochemistry & molecular biology (67) 67
therapy (67) 67
structure-activity relationship (66) 66
drug administration schedule (65) 65
isoquinolines - administration & dosage (64) 64
disease-free survival (63) 63
inhibition (63) 63
ovarian neoplasms - drug therapy (63) 63
heart failure - drug therapy (62) 62
angiotensin-converting enzyme inhibitors - administration & dosage (61) 61
clinical trials as topic (61) 61
muscarinic antagonists - adverse effects (61) 61
antitumor-activity (59) 59
expression (59) 59
heart rate - drug effects (59) 59
neoplasms - drug therapy (59) 59
urinary incontinence (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1479) 1479
Russian (32) 32
German (31) 31
Chinese (12) 12
Japanese (11) 11
French (10) 10
Italian (10) 10
Czech (3) 3
Spanish (3) 3
Bulgarian (2) 2
Korean (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 1, Issue 1, p. CD005429
Journal Article
Drugs, ISSN 0012-6667, 11/2015, Volume 75, Issue 17, pp. 1993 - 2016
Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | IMMUNOTOXIN RFB4(DSFV)-PE38 BL22 | PEGYLATED LIPOSOMAL DOXORUBICIN | EPOTHILONE-B ANALOG | DRUG-RESISTANT PHENOTYPE | GEMTUZUMAB OZOGAMICIN | PHASE-I TRIAL | METASTATIC BREAST-CANCER | ERIBULIN MESYLATE E7389 | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ANTI-MESOTHELIN IMMUNOTOXIN | CHRONIC MYELOID-LEUKEMIA | Dioxoles - therapeutic use | Diphtheria Toxin - pharmacology | Recombinant Fusion Proteins - pharmacology | Furans - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Epothilones - pharmacology | Drug Discovery - methods | Antineoplastic Agents - therapeutic use | Biological Products - pharmacology | Epothilones - therapeutic use | Harringtonines - therapeutic use | Furans - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Diphtheria Toxin - therapeutic use | Immunoconjugates - pharmacology | Cytochalasins - pharmacology | Dioxoles - pharmacology | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Ketones - therapeutic use | Cytochalasins - therapeutic use | Biological Products - therapeutic use | Ketones - pharmacology | Tetrahydroisoquinolines - pharmacology | Tetrahydroisoquinolines - therapeutic use | Withanolides - pharmacology | Harringtonines - pharmacology | Interleukin-2 - pharmacology | Withanolides - therapeutic use | Antimitotic agents | Care and treatment | Chemotherapy | Usage | Clinical trials | Dosage and administration | Diagnosis | Antineoplastic agents | Cancer | Index Medicus | Review
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 06/2012, Volume 156, Issue 12, pp. 861 - 874
Background: Urinary incontinence (UI) in women adversely affects quality of life. Purpose: To conduct a systematic literature review of drugs for urgency UI in... 
OVERACTIVE BLADDER SYNDROME | MEDICINE, GENERAL & INTERNAL | DAILY TROSPIUM CHLORIDE | SELECTIVE RECEPTOR ANTAGONIST | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | RANDOMIZED CONTROLLED-TRIAL | SEXUALLY ACTIVE WOMEN | EXTENDED-RELEASE TOLTERODINE | ANTIMUSCARINIC AGENT SOLIFENACIN | PATIENT-REPORTED OUTCOMES | Cresols - therapeutic use | Benzilates | Humans | Muscarinic Antagonists - adverse effects | Cresols - adverse effects | Solifenacin Succinate | Pyrrolidines - adverse effects | Muscarinic Antagonists - therapeutic use | Phenylpropanolamine - adverse effects | Phenylpropanolamine - therapeutic use | Pyrrolidines - therapeutic use | Benzhydryl Compounds - adverse effects | Comparative Effectiveness Research | Quinuclidines - therapeutic use | Nortropanes - adverse effects | Mandelic Acids - therapeutic use | Tolterodine Tartrate | Female | Nortropanes - therapeutic use | Mandelic Acids - adverse effects | Benzhydryl Compounds - therapeutic use | Quinuclidines - adverse effects | Benzofurans - therapeutic use | Tetrahydroisoquinolines - adverse effects | Tetrahydroisoquinolines - therapeutic use | Benzofurans - adverse effects | Randomized Controlled Trials as Topic | Urinary Incontinence - drug therapy | Quality of Life | Urinary incontinence | Research | Demographic aspects | Drug therapy | Patient outcomes
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1803 - 1813
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 02/2012, Volume 167, Issue 2, pp. 195 - 205
Summary OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES Metabolic Diseases, Host Responses, Allergies, Autoinflammatory Diseases, Type 1... 
cancer | myeloid cells | tumour‐associated macrophages | inflammation | angiogenesis | Angiogenesis | Myeloid cells | Inflammation | Tumour-associated macrophages | Cancer | MIGRATION-STIMULATING FACTOR | tumour-associated macrophages | INVASIVE MARGIN | IMMUNOLOGY | LIVER-CANCER | IN-VIVO | GENE-EXPRESSION | NF-KAPPA-B | ALTERNATIVE ACTIVATION | T-CELLS | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Tumor Escape - drug effects | Dioxoles - therapeutic use | Prognosis | Humans | Neoplasm Proteins - physiology | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Molecular Targeted Therapy | Cytokines - physiology | Neovascularization, Pathologic - pathology | Neoplasm Invasiveness - pathology | Neovascularization, Pathologic - immunology | Tumor Escape - immunology | Macrophages - physiology | Cytokines - therapeutic use | Macrophages - classification | Pyridines - administration & dosage | Neoplasm Invasiveness - immunology | Tetrahydroisoquinolines - therapeutic use | Immunity, Innate | Chemotaxis | Disease Progression | Neoplasms - drug therapy | Tumor Microenvironment - immunology | Animals | Apoptosis - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms - immunology | Clodronic Acid - therapeutic use | Macrophages - drug effects | Clodronic Acid - administration & dosage | Mice | Cytokines - antagonists & inhibitors | Liposomes | Neoplasms - pathology | Development and progression | Macrophages | Type 1 diabetes | Health aspects | Medical prognosis | Metabolic disorders | Immune system | Pathogens | Polarization | Cell survival | Immune response | Diabetes mellitus | Hypersensitivity | Leukocytes (mononuclear) | Malignancy | Suppressor cells | Metastases | Phagocytes | Monocytes | Reviews | Microenvironments | Injuries | Review
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2015, Volume 26, Issue 5, pp. 914 - 920
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2013, Volume 23, Issue 2, pp. 249 - 262
Journal Article